Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 283

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials

Chronic Myeloid Leukemia Trialists' Collaborative Group · 1997 · JNCI Journal of the National Cancer Institute

Abstract

Background: Several randomized clinical trials in chronic myeloid leukemia (CML) have reported better patient survival with interferon alfa (IFN α) than with standard chemotherapeutic agents, such as busulfan or hydroxyurea. However, the size and persistence of this survival benefit is uncertain. Our aim was to assess these reliably, both overall and in particular patient subgroups. Methods: We collaborated in a worldwide overview of all clinical trials in which patients with CML were randomly assigned to receive either IFN α as the main drug or standard chemotherapy. Trials were identified by electronic and hand searching of the medical literature and databases and by personal contact. Individual patient data were available for each of 1554 patients who had been randomly assigned to treatment in seven trials (German, Italian, British, French, Japanese, and “Benelux”). Intentionto- treat stratified logrank survival analyses were performed, reporting two-sided P values. Results: Almost all of the patients in these trials had disease with the Philadelphia chromosome abnormality. Among those who did, the regimens that involved IFN α produced a statistically significantly better survival than those involving either hydroxyurea ( P = .001) or busulfan ( P = .00007) alone. The 5-year survival rates were 57% with IFN α and 42% with chemotherapy, with an absolute difference of 15% (standard deviation = 3%; P <.00001). There were no trials or subgroups of patients in which the treatment difference was statistically significantly different from the average. Conclusion: For patients with Philadelphia chromosome-positive chronic myeloid leukemia, the inclusion of IFN α in the therapeutic regimen produced substantially better 5-year survival than standard chemotherapy alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/89.21.1616

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 283

Metadata

Authors
Chronic Myeloid Leukemia Trialists' Collaborative Group
Venue
JNCI Journal of the National Cancer Institute
Published
1997-11-05
Volume
89
Issue
21
Pages
1616-1620
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2508058084
Cited by
283
References
12
FWCI
3.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials. https://app.cochat.ai/papers/10.1093/jnci/89.21.1616
The paper
Chronic Myeloid Leukemia Trialists' Collaborative Group. (1997). Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/89.21.1616

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.